Trial Profile
Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharnygeal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2020
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 02 May 2020 Status changed from active, no longer recruiting to completed.
- 12 May 2014 Planned End Date changed from 1 Feb 2017 to 1 Oct 2019.
- 05 Apr 2012 Additinal lead trial centre (Second Military Medical University) added as reported by as reported by ClinicalTrials.gov.